Huadao Biology
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Huadao Biology - overview
Established
2017
Location
Shanghai, -, China
Primary Industry
Biotechnology
About
Based in Shanghai, China, and established in 2017, Huadao Biology is a cellular immunity therapy technology provider that focuses on R&D of cell therapy drugs and industry chain production technology. The company is a high-tech biomedicine enterprise. Also, it is the only CAR-T cell drug R&D company with independent intellectual property rights in China. The company is building cell drug R&D and transformation production bases in six central cities in China.
In February 2024, the firm closed a series D+ funding. In October 2025, Huadao Biology closed series D+2 funding led by returning investor Boai Nky Medical Holdings Ltd. , with participation from new investor Jinghu Fund, and other investors. The company developed the CAR-T cell products industry chain production system, which includes engineered bacteria fermentation, plasmid purification, virus packaging, virus purification, T cell acquisition, T cell transfection, and freezing.
Up to 2021, it has carried out R&D of nearly 30 cases of CD19- CAR-T in the treatment of acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. Also, it developed the preclinical cytlogy of CAR vectors for other tumors, such as gastric cancer, liver cancer, pancreatic cancer, and glioma. The company plans to build Huadao Biology Songjiang base phase II project. Also, it will compete HD CD19 CAR-T injection phase II clinical trial.
Current Investors
CCB Private Equity Investment Management, Oceanpine Capital, Baichuan Huida Investment
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Verticals
Manufacturing
Company Stage
Series D
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.